Target Price | $42.07 |
Price | $40.21 |
Potential | 4.62% |
Number of Estimates | 15 |
15 Analysts have issued a price target Exelon 2025 . The average Exelon target price is $42.07. This is 4.62% higher than the current stock price. The highest price target is $46.00 14.40% , the lowest is $38.00 5.50% . | |
A rating was issued by 22 analysts: 6 Analysts recommend Exelon to buy, 15 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Exelon stock has an average upside potential 2025 of 4.62% . Most analysts recommend the Exelon stock at Hold. |
11 Analysts have issued a sales forecast Exelon 2024 . The average Exelon sales estimate is $21.8b . This is 4.28% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $23.0b 1.20% , the lowest is $19.9b 12.74% .
This results in the following potential growth metrics:
2023 | $21.7b | 13.89% |
---|---|---|
2024 | $21.8b | 0.23% |
2025 | $22.3b | 2.21% |
2026 | $22.9b | 3.07% |
2027 | $23.7b | 3.32% |
2028 | $24.0b | 1.45% |
9 Analysts have issued an Exelon EBITDA forecast 2024. The average Exelon EBITDA estimate is $8.3b . This is 6.11% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $8.5b 9.22% , the lowest is $7.9b 1.40% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $7.5b | 9.65% |
---|---|---|
2024 | $8.3b | 9.61% |
2025 | $8.8b | 6.68% |
2026 | $9.4b | 6.80% |
2027 | $10.4b | 10.10% |
2028 | $11.1b | 6.91% |
2023 | 34.74% | 3.72% |
---|---|---|
2024 | 37.99% | 9.35% |
2025 | 39.65% | 4.37% |
2026 | 41.09% | 3.63% |
2027 | 43.78% | 6.55% |
2028 | 46.14% | 5.39% |
6 Exelon Analysts have issued a net profit forecast 2024. The average Exelon net profit estimate is $2.4b . This is 1.19% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 1.41% , the lowest is $2.4b 0.83% .
This results in the following potential growth metrics and future Net Margins:
2023 | $2.3b | 6.36% |
---|---|---|
2024 | $2.4b | 4.65% |
2025 | $2.6b | 7.45% |
2026 | $2.8b | 5.16% |
2027 | $3.0b | 6.80% |
2028 | $3.2b | 6.60% |
2023 | 10.77% | 6.60% |
---|---|---|
2024 | 11.24% | 4.36% |
2025 | 11.82% | 5.16% |
2026 | 12.06% | 2.03% |
2027 | 12.47% | 3.40% |
2028 | 13.10% | 5.05% |
6 Analysts have issued a Exelon forecast for earnings per share. The average Exelon <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $2.45 . This is 1.24% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $2.45 1.24% , the lowest is $2.44 0.83% .
This results in the following potential growth metrics and future valuations:
2023 | $2.34 | 6.36% |
---|---|---|
2024 | $2.45 | 4.70% |
2025 | $2.63 | 7.35% |
2026 | $2.77 | 5.32% |
2027 | $2.96 | 6.86% |
2028 | $3.15 | 6.42% |
Current | 16.58 | 6.49% |
---|---|---|
2024 | 16.42 | 0.97% |
2025 | 15.28 | 6.94% |
2026 | 14.53 | 4.91% |
2027 | 13.61 | 6.33% |
2028 | 12.77 | 6.17% |
Based on analysts' sales estimates for 2024, the Exelon stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.90 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 1.85 .
This results in the following potential growth metrics and future valuations:
Current | 3.73 | 6.52% |
---|---|---|
2024 | 3.90 | 4.59% |
2025 | 3.82 | 2.16% |
2026 | 3.70 | 2.98% |
2027 | 3.58 | 3.22% |
2028 | 3.53 | 1.43% |
Current | 1.77 | 6.47% |
---|---|---|
2024 | 1.85 | 4.48% |
2025 | 1.81 | 2.17% |
2026 | 1.75 | 2.98% |
2027 | 1.70 | 3.22% |
2028 | 1.67 | 1.43% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.